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SUMMARY

Purpose: Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction.
Previous analyses of results from a prospective, observational study assessing vigabatrin-induced
visual field constriction (described below) employed a partially subjective interpretation of static
perimetery. In an effort to affirm these previous findings through more objective, quantitative
methodology, we now report data from a subset analysis of refractory partial epilepsy patients in
the study who underwent Goldmann kinetic perimetry.
Methods: Patients aged ≥8 years with refractory partial seizures were enrolled and grouped:
those receiving vigabatrin for ≥6 months (Group I); those who had received vigabatrin for ≥6
months and then had discontinued for ≥6 months (Group II); and those naïve to vigabatrin
(Group III). Patients underwent static or kinetic perimetry or both every 4–6 months for ≤3
years. For kinetic perimetry, the temporal and nasal visual fields were measured along the
horizontal meridian with the largest (V4e, IV4e) and smallest (I2e, I1e) isopters, respectively.
Results: Of 735 patients enrolled, 341 had Goldmann perimetry data. Of these, 258 received
vigabatrin. Sixteen percent of vigabatrin-exposed patients had moderate visual field defects
(30°–60° retained temporal vision), and 3% had severe defects (<30° retained temporal vision).
Visual function questionnaire results indicated a weak correlation between visual field
constriction severity and visual symptoms.
Conclusions: These results affirm both an analysis of the same study based primarily on static
perimetry and findings from cross-sectional studies. The present analysis verifies that visual field
constriction, when it occurs, is most often mild or moderate and is not associated with symptoms
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of abnormal visual function. The clinical decision to prescribe vigabatrin should be based on a
benefit-risk analysis for each individual patient.
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1.

INTRODUCTION

Vigabatrin (Sabril), a selective and irreversible γ-aminobutyric acid transaminase inhibitor
(Ben-Menachem, 1995), is effective as adjunctive therapy for adult patients with refractory
complex partial seizures (Bruni et al., 2000, French et al., 1996, Guberman and Bruni, 2000,
Sander et al., 1990) and as monotherapy for infants with infantile spasms (West syndrome)
(Aicardi et al., 1996, Appleton et al., 1999, Chiron et al., 1990, Chiron et al., 1997, Elterman et
al., 2001, Wohlrab et al., 1998). Vigabatrin has been approved for these indications in the United
States since 2009, and in many other countries since 1989. Despite its proven efficacy, the use of
vigabatrin has been limited by the associated risk of retinopathy, characterized by irreversible,
bilateral constriction of the visual fields, an adverse reaction to the drug first reported in 1997
(Eke et al., 1997). Since then, several reports have described this very specific visual field defect
in vigabatrin-treated patients (Baulac et al., 1998, Harding, 1998, Kalviainen and Nousiainen,
2001, Lawden et al., 1999, Nicolson et al., 2002, Wild et al., 1999, Wilson and Brodie, 1997),
and systematic retrospective (Besch et al., 2002, Hardus et al., 2000, Kalviainen and Nousiainen,
2001, Kalviainen et al., 1999, Newman et al., 2002, Nicolson et al., 2002, Stefan et al., 2000,
Vanhatalo et al., 2002, Wild et al., 1999) and prospective (Schmitz et al., 2002) analyses have
suggested that it may occur in a significant number of treated patients (reported range, 14%92%). This large range is influenced by differing visual field testing methods, as well as the
criteria defining abnormal fields. The visual field defect generally is asymptomatic (Wild et al.,
1999), possibly a result of, in part, the relative sparing of the central retina. However, there is
electrophysiologic evidence, using multifocal electroretinography, that vigabatrin causes a
reduction in function within the central retina. Other studies have reported mild decreases in
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color vision (Johnson et al., 2000) and reductions in grating acuity in children (Durbin et al.,
2009).

In response to concerns of the European Medicines Agency, Sanofi-Aventis, the manufacturer of
vigabatrin outside of North America, conducted a large cross-sectional study (Study 4020) with a
prospective follow-up to further investigate vigabatrin-induced visual field constriction in
pediatric and adult patients being treated for partial epilepsy. The study was designed to assess
the frequency of the vigabatrin-induced visual field constriction, better characterize the
functional consequences of the visual defect, and determine risk factors for its development. An
interim analysis of this study and a partial analysis of the final data have been published. In these
analyses, the primary outcome measure, the presence or absence of bilateral, concentric,
peripheral constriction (BCPC) of the visual fields, was based on a global assessment of the
perimetry data for each patient through partially specified criteria and predominantly static
perimetry. The analysis of the final data set found that, among 524 evaluable patients with 1 or
more conclusive perimetry examinations, the frequency of BCPC at the last conclusive
examination was greatest for patients receiving vigabatrin at study entry: 26.3% for patients aged
8–12 years and 43.3% for patients aged >12 years (Wild et al., 2009). For patients who had
discontinued vigabatrin for ≥6 months, the frequencies were 14.9% for children and 24.5% for
adults. Further, this report found that the risk of developing BCPC was correlated significantly
with duration of vigabatrin therapy, mean daily dosage, and male sex. Among 386 vigabatrinexposed patients, visual field loss was graded mild for 15.8%, moderate for 10.6%, and severe
for 3.9%, based on a complex grading system applied to data from both static and kinetic
perimetry. Moreover, no relationship was found between the presence of symptoms of visual
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difficulties ascertained by questionnaire and vigabatrin-induced visual field constriction (Wild et
al., 2009).

While for many patients, static perimetry has very low test/retest variability, for other patients,
the rigor of the testing procedures, combined with possible fatigue and decreased cognitive
function, produces high coefficients of variability. Because of the subjective nature of static
perimetery for some patients, we sought to verify the findings of the previous research by
conducting objective and quantitative analyses to affirm the rates and severity of vigabatrininduced visual field constriction previously observed. Through the present analyses, we provide
the results for a subset of 341 patients in Study 4020 who underwent Goldmann kinetic
perimetry.
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2.

METHODS

2.1

Study Design

This was an open-label, multicenter, comparative study conducted at 46 sites in France, South
Korea, Italy, Spain, and Australia. Male and female patients ≥8 years of age with refractory
partial seizures for ≥1 year were eligible. Patients were classified into 6 groups defined by 2 age
groups and 3 treatment groups (Table 1). Children were 8–12 years of age, and adults were >12
years. Group I was composed of patients who were receiving vigabatrin at study entry and who
had been treated with vigabatrin as either monotherapy or polytherapy for ≥6 months before
study entry. Group II included patients who were treated with other antiepileptic drugs (AEDs)
for ≥6 months but who had previously received vigabatrin for ≥6 months and had discontinued
vigabatrin ≥6 months prior to study entry. Patients in Group III were treated with other AEDs
and had never received vigabatrin. However, these patients were permitted to initiate treatment
with vigabatrin during the study. Patients with identified primary ophthalmologic pathology were
excluded. All patients, or their caregivers, provided written informed consent.

This study consisted of an initial screening/randomization phase, baseline visit, and a follow-up
phase of up to 36 months. The baseline ophthalmologic assessments included ocular history and
symptoms, listing of all ocular medications taken during the past 6 months, eye color, visual
acuity, manifest refraction, slit-lamp biomicroscopy, intraocular pressure, bilateral dilated
ophthalmoscopy, gonioscopy, perimetry, determination of whether any ocular findings might
explain abnormal visual field results, and visual disability as assessed by a questionnaire.
Perimetry (static, kinetic, or both) was repeated every 4–6 months at each follow-up visit. Sites
were allowed to choose the perimetry device and protocol employed within broad parameters. A
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site did not necessarily employ a consistent methodology, even for different visits of an
individual patient.

A subset of patients underwent kinetic perimetry testing — the vast majority via the Goldmann
perimeter and the balance through the Moniteur device. The data from Goldmann perimetry were
subjected to post-hoc analysis. Digital files of scanned perimetry records from these tests were
submitted to an independent contract research organization (ORA Clinical Research and
Development, Andover, MA, USA), which measured the extent of the visual fields along the
horizontal meridian while blinded to treatment group. Measurements were conducted for the
largest isopter tested in the temporal field and the smallest isopter tested in the nasal field. The
majority of the data available were from the V4e and IV4e temporal isopters and the I2e and I1e
nasal isopters. Because of non-uniformity between or within sites regarding the isopters tested,
the data are presented in 2 ways. First, the measurements for the largest temporal and smallest
nasal isopters tested were combined to generate summary data representing all the observations.
Second, as a way of guarding against misleading results from combining disparate
measurements, the measurements were analyzed separately for the 2 temporal and 2 nasal
isopters with the most data.

At each study visit, patients completed a 19-item visual function questionnaire, primarily
consisting of questions concerning peripheral vision (eg, do you bump into doors, do you have
trouble catching a ball).
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2.2

Treatment

The dosage and regimen of vigabatrin were not protocol-determined, with the exception of 7
patients in Group III who were prescribed vigabatrin after enrollment. For these patients, the
daily starting dosages were 1 g/day for adults and 40 mg/kg for children, and these dosages could
be titrated up to 2–3 g/day for adults and 80–100 mg/kg for children. All other patients were
allowed to continue the AED treatment they were receiving at study entry, with dosage
adjustments as deemed necessary by their physicians.

2.3

Data Analysis

Measurements employed in the analyses of the largest temporal and smallest nasal isopters were
from the last perimetry obtained for each patient during the study. For an individual isopter, the
data were from the last perimetry obtained with that isopter, which was not necessarily the final
perimetry obtained during the study.
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3.

RESULTS

3.1

Patients

A total of 735 patients enrolled in the study (Figure 1). Measurements of extent of visual fields
based on kinetic perimetry were obtained for 359 patients. Of these 359, 341 had undergone
Goldmann perimetry and 18 had completed perimetry with the Moniteur device. Of the 341
patients who completed Goldmann perimetry, 258 were exposed to vigabatrin and 83 were naive
to the drug. The distribution of these patients by treatment and age groups is shown in Table 1,
and baseline characteristics are provided in Table 2. Distribution by sex was approximately equal
in adults, but there was a male preponderance among children. Mean age at study entry was 10.3
years for children and 33.1 years for adults. At study entry, the median duration of vigabatrin
treatment was 4.1 years for both children and adults in Group I, and 1.6 years for children and
2.5 years for adults in Group II. For children and adults in Groups I and II, mean time from first
vigabatrin dose to first perimetry examination ranged from 4.0 to 5.7 years. Most baseline
characteristics of patients in Group III were similar to those of patients treated with vigabatrin,
except that patients in Group III had shorter AED exposure times than those in either Group I or
Group II. Moreover, the subset of patients who had undergone kinetic perimetry generally was
representative of the entire group of patients in the study. However, in this subset, the median
durations of vigabatrin exposure were shorter for adults in Group I (3.5 vs. 4.6 years) and
children in Group II (1.6 vs. 3.0 years).

3.2

Perimetry

The extent of visual field impairment was analyzed for the subset of 341 patients who had
completed Goldmann perimetry. All patients had data for the temporal field, and all but 2 had
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data for the nasal field. Based on combined data for the largest isopter tested, monocular
temporal field at final Goldmann perimetry for the 258 vigabatrin-exposed patients ranged from
13° to 90°, and averaged 71.1°±14.7° (Table 3 and Figure 2a). When analyzed for the V4e and
IV4e isopters, for which the most data were available, the mean retained temporal fields for
vigabatrin-exposed patients were 73.5° ±15.3° (range, 12°–90°) and 69.1°±15.4° (range, 7°–90°),
respectively.

Monocular nasal fields of vigabatrin-exposed patients, based on the smallest isopter tested,
ranged from 0° to 64°, averaging 19.7°±10.8° (Table 3 and Figure 2b). When analyzed for the
I2e and I1e isopters, for which the most data were available, the mean retained nasal fields were
19.0°±8.3° (range, 4°–37°) and 13.2°±7.1° (range, 3°–36°), respectively.

The perimetry results from vigabatrin-exposed and vigabatrin-naïve patients exhibited modest
differences. Depending on the isopters compared, the mean retained temporal field was between
6.9° and 8.9°greater for vigabatrin-naïve patients, while the difference in mean retained nasal
field varied between 1.8° and 2.4° (Table 3). Cumulative frequency distribution of retained
visual field from the combined isopter data demonstrates modest differences between the
vigabatrin-exposed and vigabatrin-naïve patients (Figure 2).

The retained temporal fields were classified as normal (>80° retained field, averaged for the 2
eyes), mildly impaired (60°–80°), moderately impaired (30°–<60°), and severely impaired
(<30°). The distributions of temporal visual field impairment at the last kinetic perimetry
examination for the largest isopter tested for vigabatrin-exposed and vigabatrin-naïve patients are
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shown in Figures 3a and 3b, respectively. Of vigabatrin-exposed patients, the majority were
unimpaired or had mild or moderate impairment of temporal visual fields, while 2% had severe
impairment. Another approach employed data for vigabatrin-naïve patients to calculate the
retained visual field measurements representing the fifth, tenth, and twenty-fifth percentiles and
applied those percentile ranges to the vigabatrin-exposed patients. By these criteria, for the
temporal field results of the largest isopters tested, 20.2% of vigabatrin-exposed patients were
within the fifth percentile (61.5°), 28.7% were within the tenth percentile (65.5°), and 41.5%
were within the twenty-fifth percentile (71.5°).

3.3

Visual Symptoms

Results from the questionnaire, which assessed visual symptoms, such as bumping into objects
and having difficulty catching a ball, showed only a weak correlation between perimetry results
and symptoms of visual disability. When patients who had completed Goldmann perimetry were
stratified according to the severity of visual field defect, as described in Section 3.2, we found a
weak (r=0.16) but statistically significant (P=0.005) correlation between severity of visual field
defect and answering “yes” to at least 1 item of the 19-item questionnaire (data not shown).
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4.

DISCUSSION

The original study sought to estimate the prevalence and incidence of visual field defect for
children and adults treated with vigabatrin for refractory partial epilepsy and to identify risk
factors for their occurrence (Wild et al., 2009). It included the largest group of vigabatrinexposed epilepsy patients ever systematically evaluated for vision loss. The primary outcome
measure was a qualitative determination of bilateral, concentric, peripheral constriction (BCPC)
by a single visual field expert who was blinded to treatment group, but who had access to all
perimetry data for each patient. Some patients underwent both static and kinetic perimetry at the
same visit, and for those patients, the reviewer placed greater weight on static perimetry (Wild et
al., 2009). The criteria used for determining BCPC have been described previously (Wild et al.,
1999). The advantages of this qualitative approach include consistency and the ability to
incorporate all available perimetry data for each patient, while the disadvantages of the approach
are a lack of objective, protocol-specified BCPC criteria and potential bias.

In addition to the outcome measurement, this analysis had several limitations. First, the study
included only 7 patients who had initiated vigabatrin therapy during the study (6 of whom had
Goldmann perimetry and none of whom developed visual field constriction). Second, baseline
data were not available for any of the remaining patients. Third, given that ≥6 months of
vigabatrin exposure was required for Groups I and II and the mean exposure at enrollment was
actually between 1.6 and 4.1 years for all groups, the earliest onset of visual field constriction
during vigabatrin therapy could not be assessed in this study. Instead, cases of vigabatrininduced visual field constriction were detected only after several months or years of vigabatrin
exposure. By contrast, a well-characterized case of visual field constriction has been reported
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after only 4 months of vigabatrin exposure (Malmgren et al., 2001). The literature contains a
dearth of reports of visual field testing for patients with shorter durations of drug exposure.
Fourth, the study lacked a uniform testing method between the 46 sites or even within a single
site. Finally, the study collected vigabatrin exposure data retrospectively. However, despite its
limitations, this study was the largest to assess vision effects in vigabatrin-treated patients,
providing an estimate of the frequency and severity of visual field constriction with durations of
vigabatrin exposure between 6 months and approximately 5 years.

The current paper complements the previously published analysis of this same study (Wild et al.,
2009). This analysis employed quantitative measurements of the visual field along the horizontal
meridian from kinetic perimetry to estimate the severity of visual field defects. While this
quantitative approach was limited by the lack of uniformity in perimetry methodology (in
particular the failure to test the same isopters for all patients at all visits), we mitigated that
limitation by analyzing data from individual isopters to support the findings and to summarize
the entire data set with descriptive statistics for combined measurements of several isopters.

No generally agreed upon categorization of the severity of visual field defect exists. The severity
categories chosen for the current analysis were intended to reflect the degree of resulting
functional limitation. For example, 120° of total width of the horizontal visual field (equivalent
to 60° of monocular temporal vision) is the limit for having a driver’s license in many
jurisdictions and was chosen as the dividing line between mild and moderate defect. The
criterion of <30° for a severe deficit is similar to that chosen for several published studies based
on kinetic perimetry. Importantly, the categories employed here are not commensurate with those
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employed by Wild et al (Wild et al., 2009). Moreover, the duration of vigabatrin exposure was
somewhat shorter in the subgroup of patients undergoing Goldmann perimetry than in the entire
study population.

The quantitative assessment of kinetic perimetries (Figure 3) demonstrated that the majority of
vigabatrin-exposed patients had some constriction of the visual fields. However, this should be
compared with the finding that 45% of vigabatrin-naïve patients also had retained temporal
visual field <80°. The majority of vigabatrin-induced visual field defects were mild to moderate
(Figure 3). Nevertheless, severe visual field constriction to <30° of retained monocular temporal
visual field, corresponding to a total extent of binocular vision of <60°, occurred in 2% of
patients. In spite of the differences between the analyses, Wild and colleagues (Wild et al., 2009)
found that 15 of 386 patients (4%) in Groups I and II had severe vigabatrin-attributed visual field
loss, which is similar to the findings of our present analysis. However, in contrast to the analysis
of Wild and colleagues (Wild et al., 2009), we found a weak correlation between answering
“yes” to at least 1 question on the visual function questionnaire and severity of the visual field
defect.

In the assessment of patients receiving vigabatrin, this analysis does not demonstrate that kinetic
perimetry is necessarily superior to static perimetry. It is the clinician’s decision which method
should be used for an individual patient. For some patients, (for example, those who are lethargic
or have attention deficits), kinetic perimetry may be preferable, as it provides for more humanto-human interaction and monitoring. On the other hand, for those are alert, cognitive intact, and
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engaged, static perimetry may be appropriate. One size does not fit all, and judgment on patientby-patient basis is warranted.

In conclusion, this analysis of data from the largest cross-sectional study conducted to date of
perimetry in patients treated with vigabatrin for refractory partial epilepsy verifies that visual
field constriction, when it occurs, is most often mild or moderate and is not associated with
symptoms of abnormal visual function. However, for a minority of patients exposed to vigabatrin
for months to years, the visual field constriction can be severe and symptomatic.
The clinical decision to prescribe vigabatrin should be based on a benefit-risk analysis for each
individual patient. Peripheral visual field constriction caused by vigabatrin is asymptomatic for
most patients, and, thus, periodic ophthalmologic testing (including perimetry) is required to
detect the defect. For patients with refractory complex partial epilepsy who do not experience a
substantial improvement in seizure control after 1- to 3-month trials of vigabatrin, the drug
should be discontinued to minimize the risk of vision loss. For patients who receive substantial
benefit from vigabatrin, periodic ophthalmologic testing is recommended to help guide
physicians in their ongoing benefit-risk analyses for all patients (Sergott et al., 2010).
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TABLES

Table 1. Study group based on age and treatment history (patients with Goldmann
perimetry data)
Patients, n
Group

Children
(8–12 years)

Adults
(>12 years)

I

Patients currently being treated with
vigabatrin for ≥6 months

28

92

II

Patients previously treated with
vigabatrin for ≥6 months who had
discontinued for ≥6 months before
study entry

32

100

Patients never treated with vigabatrin
before study entry*

22

67

III

*6 patients in Group III began receiving vigabatrin during the course of the study and
are included in the data analyses for both the vigabatrin-exposed and vigabatrin-naïve
groups.
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Table 2. Baseline characteristics of the study groups
Children (n=82)

Adults (n=259)

Characteristic

Group I
(n=28)

Group II
(n=32)

Group III
(n=22)

Group I
(n=92)

Group II
(n=100)

Group III
(n=67)

Sex, n (%)
Male
Female

14 (50.0)
14 (50.0)

20 (62.5)
12 (37.5)

14 (63.6)
8 (36.4)

40 (43.5)
52 (56.5)

54 (54.0)
46 (46.0)

29 (43.3)
38 (56.7)

Mean age, years ±SD

10.3±1.4

10.1±1.3

10.5±1.3

33.0±15.3 33.2±14.5

33.0±14.3

Mean duration of vigabatrin
dosing at study entry, years
±SD

4.1±2.8

1.6±1.7

NA

4.1±2.6

2.5±2.2

NA

Mean time from first
vigabatrin dose to first
perimetry examination,
years ±SD

4.1±2.8
(n=28)

4.0±2.5
(n=31)

NA

4.1±2.6
(n=92)

5.7±2.8
(n=100)

NA

Mean duration of AED use,
years ±SD

4.4 ± 3.0
(n=21)

4.1 ± 3.0
(n=32)

3.3 ± 1.9
(n=22)

9.6 ± 7.6
(n=83)

8.8 ± 7.5
(n=97)

10.0 ± 10.0
(n=67)

AED=antiepileptic drug; NA=not applicable; SD=standard deviation.

Table 3. Degrees of retained visual field along the horizontal meridian.
Group

Isopter

n

Mean

Median

Minimum

Maximum

SD

Largest

258

71.1

73.0

13.0

90.0

14.7

V4e

135

73.5

77.0

11.5

90.0

15.3

IV4e

131

69.1

72.5

7.0

90.0

15.4

Largest

83

78.9

82.0

27.0

91.0

12.3

V4e

40

82.4

87.3

25.0

91.0

13.9

IV4e

38

76.0

80.0

39.5

90.0

13.7

Smallest 256

19.7

19.0

0.0

63.5

10.8

I2e

86

19.0

21.3

4.0

36.5

8.3

I1e

157

13.2

11.5

3.0

36.0

7.1

Smallest 81

21.5

20.0

3.5

46.5

11.9

I2e

28

21.8

24.8

0.0

37.0

10.5

I1e

44

15.6

14.5

4.0

41.0

8.7

Temporal Field
VGB-exposed

VGB-naïve

Nasal Field
VGB-exposed

VGB-naïve

SD=standard deviation; VGB=vigabatrin.

FIGURE LEGENDS

Figure 1. Distribution of patients who underwent kinetic perimetry.

Figure 2. Cumulative distribution of degrees in the (A) temporal visual field at final
perimetry in vigabatrin-exposed (n=258) and vigabatrin-naïve patients (n=83) and (B)
nasal visual field at final perimetry in vigabatrin-exposed (n=256) and vigabatrin-naïve
(n=81) patients.

Figure 3. Severity of visual field defect at last kinetic perimetry in (A) vigabatrin-exposed
and (B) vigabatrin-naïve patients. Unimpaired: >80° monocular temporal field retained; Mild:
60°–80° monocular temporal field retained; Moderate: 30°–60° monocular temporal field
retained; Severe: <30° monocular temporal field retained. Measurements are of largest isopter
tested at final Goldmann perimetry.
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